News & Resources / All News

Veredus Laboratories Announces CE-IVD Marking of VereCoV™ Detection Kit for Diagnosis of COVID-19

Veredus Laboratories Pte Ltd “Veredus” today announced the CE-IVD marking of VereCoV™ Detection Kit for commercial launch in Europe. The test is intended for the qualitative detection of 2019 novel Coronavirus (2019-nCoV) also known as SARSCoV- 2 that causes COVID-19.


The kit was developed to provide an easy-to-use solution for clinical testing, public health surveillance and detection of the coronavirus from nasal or nasopharyngeal swab specimen to enable authorities to take appropriate actions. The test integrates PCR amplification and microarray for rapid qualitative detection of 2019-nCoV with the additional capability to detect a subset of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) simultaneously with the same test.


“We are ready to respond effectively to the needs of hospitals and reference laboratories by providing a quality molecular testing solution for the pandemic,” says Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.

A pilot study: VereMTB detection kit for rapid detection of multidrug-resistant mycobcterium tuberculosis in clinical sputum samples

The performance of VereMTBTM Detection Kit for detection of multidrug-resistant tuberculosis (MDR-TB) was validated by using 124 sputum samples. Comparing with MGIT culture, the sensitivity and specificity of VereMTB Detection Kit for MTBC detection were 97.0% and 98.3%, respectively. Compared with MGIT DST, the sensitivity and specificity of VereMTB Detection Kit for RIF resistance detection were 85.7% and 93.9%, respectively, and the sensitivity and specificity of VereMTB Detection Kit for INH resistance detection were 75.0% and 95.7%, respectively. 6 NTM samples were also detected and identified correctly. The VereMTB Detection Kit can detect MDR-TB rapidly and accurately in sputum samples from TB suspects.

Click here to read more

Veredus Laboratories to support the bio-surveillance detection of 2019-nCoV (SAR-CoV-2) at Singapore checkpoints

In the light of recent developments related to the ongoing COVID-19 outbreak, Veredus Laboratories is supporting the bio-surveillance detection efforts by swab tests from travellers at land, sea and air checkpoints in Singapore. Using the VerePLEX™ Biosystem that utilises the Lab-on-Chip technology, the VereCoV™ Detection Kit is used for the multiplexed screening and detection of the viral nucleic acid.

For more information on the additional precautionary measures in response to the global situation of escalating COVID-19 infection, please refer to the Ministry of  Health Singapore website at https://www.moh.gov.sg/news-highlights/details/additional-precautionary-measures-in-response-to-escalating-global-situation to find out more.

Learn more about the swab test that has been implemented at Singapore checkpoints beginning 4March 2020 at http://bit.ly/2vEfKmb .

Veredus Laboratories’ VereCoV™ Detection Kit receives Singapore HSA Provisional Authorisation for IVD use

Veredus Laboratories Pte Ltd “Veredus” has obtained the Provisional Authorisation from Singapore Health Sciences Authority (HSA) for its VereCoV™ Detection Kit following Veredus’ rapid launch of this kit as a “Research Use Only” (RUO) test earlier this year. With this Authorisation, VereCoV™ Detection Kit can be used directly by laboratories or hospitals to test patients for clinical diagnosis.

Veredus Laboratories Announces the Development of a Lab-on-Chip for the detection of 3 coronaviruses: MERS-CoV, SARS-CoV and 2019-nCoV

Veredus Laboratories Pte Ltd “Veredus”, a leading provider of innovative molecular diagnostic solutions, announced today the development of VereCoV detection kit, a portable Lab-on-Chip application capable of detecting the Middle-East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and 2019 Novel Coronavirus (2019-nCoV) i.e. Wuhan Coronavirus, in a single test.

NCT CBRNe Europe Conference 2019, Vienna (Austria)

Look for us at Booth 38 during the 8th edition of Europe’s highly successful Non-Conventional Threat: CBRNe Europe 2019 that will take place 25-27 July 2019 in Intercontinental Hotel in Vienna, Austria. The three-day event will feature live CBRNe capability demonstrations, one conference stream, multiple workshops, training sessions for civil and military responders, a large indoor and outdoor industry exhibition.

Click here to read more

Announcement of New Company Logo

Dear Veredus Customers,

We are pleased to unveil our new company logo as part of synergy efforts between Veredus and our parent company SEKISUI CHEMICAL CO. LTD.

SEKISUI-Veredus will maintain “Veredus Laboratories” as a product logo on its product line. The registered company name will remain as “Veredus Laboratories Pte Ltd”.

For more information, please refer to the notification attached.

Veredus Laboratories launches VereBeef™ Detection Kit for the detection of multiple pathogens in raw beef trim

VereBeef™ Detection Kit used in conjunction with the VerePLEX™ Biosystem is best described as an integration of both multiplex PCR and microarray on a Lab-on-Chip platform (VereChip™). It was specifically developed for the qualitative detection and differentiation of Escherichia coli (E. coli) O157:H7, E. coli O26, E. coli O45, E. coli O103, E. coli O111, E. coli O121, E. coli O145, STEC virulence factors (stx1A, stx2A, eae), and Salmonella spp. in a single test using raw beef trim samples.

VereBeef Press Release Final (Singapore)

NCT CBRNe Asia Conference 2018, Hanoi (Vietnam)

Join us in Asia’s premier CBRNe event The Non-Conventional Threat: CBRNe Asia 2018 that will take place 9-11 October in Hanoi, Vietnam. Look out for us to find out more about how we can help you in biosurveillance.

Click here to read more